User login
Key clinical point: In patients with high-risk nonmetastatic prostate cancer, adding abiraterone acetate and prednisolone to androgen deprivation therapy (ADT) prolongs survival vs ADT alone.
Major finding: Add-on abiraterone acetate plus prednisolone to ADT vs ADT alone significantly improved metastasis-free survival (MFS; hazard ratio [HR], 0.53; P < .0001) and overall survival (HR, 0.60; P < .0001). There was no difference in MFS when enzalutamide and abiraterone acetate were administered concurrently vs abiraterone acetate alone (interaction HR, 1.02; P = .91).
Study details: A meta-analysis of 2 phase 3 STAMPEDE trials including 1,974 patients with high-risk nonmetastatic prostate cancer randomly assigned to ADT alone or ADT plus abiraterone acetate and prednisolone with or without enzalutamide.
Disclosures: This work was supported by Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, and others. The authors received personal fees, honoraria, grants, travel support, royalty, nonfinancial support, and payments or held patents outside this work.
Source: Attard G et al. Lancet. 2021 Dec 23. doi: 10.1016/S0140-6736(21)02437-5.
Key clinical point: In patients with high-risk nonmetastatic prostate cancer, adding abiraterone acetate and prednisolone to androgen deprivation therapy (ADT) prolongs survival vs ADT alone.
Major finding: Add-on abiraterone acetate plus prednisolone to ADT vs ADT alone significantly improved metastasis-free survival (MFS; hazard ratio [HR], 0.53; P < .0001) and overall survival (HR, 0.60; P < .0001). There was no difference in MFS when enzalutamide and abiraterone acetate were administered concurrently vs abiraterone acetate alone (interaction HR, 1.02; P = .91).
Study details: A meta-analysis of 2 phase 3 STAMPEDE trials including 1,974 patients with high-risk nonmetastatic prostate cancer randomly assigned to ADT alone or ADT plus abiraterone acetate and prednisolone with or without enzalutamide.
Disclosures: This work was supported by Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, and others. The authors received personal fees, honoraria, grants, travel support, royalty, nonfinancial support, and payments or held patents outside this work.
Source: Attard G et al. Lancet. 2021 Dec 23. doi: 10.1016/S0140-6736(21)02437-5.
Key clinical point: In patients with high-risk nonmetastatic prostate cancer, adding abiraterone acetate and prednisolone to androgen deprivation therapy (ADT) prolongs survival vs ADT alone.
Major finding: Add-on abiraterone acetate plus prednisolone to ADT vs ADT alone significantly improved metastasis-free survival (MFS; hazard ratio [HR], 0.53; P < .0001) and overall survival (HR, 0.60; P < .0001). There was no difference in MFS when enzalutamide and abiraterone acetate were administered concurrently vs abiraterone acetate alone (interaction HR, 1.02; P = .91).
Study details: A meta-analysis of 2 phase 3 STAMPEDE trials including 1,974 patients with high-risk nonmetastatic prostate cancer randomly assigned to ADT alone or ADT plus abiraterone acetate and prednisolone with or without enzalutamide.
Disclosures: This work was supported by Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, and others. The authors received personal fees, honoraria, grants, travel support, royalty, nonfinancial support, and payments or held patents outside this work.
Source: Attard G et al. Lancet. 2021 Dec 23. doi: 10.1016/S0140-6736(21)02437-5.